StockData
PharmaCyte Biotech, Inc. logo

PharmaCyte Biotech, Inc. (PMCB) stock

PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 7/30
$0.40+0.00 (+0.75%)

Close on Nov 12, 2026Market cap $4.32MP/E –Yield –

Earnings

PharmaCyte Biotech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of PharmaCyte Biotech's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2022ended Apr 30, 2022Jul 11, 2022after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

PharmaCyte Biotech has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When PharmaCyte Biotech puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases PharmaCyte Biotech filed with the SEC as exhibits to Form 8-K or 6-K

  1. PRESS RELEASE DATED SEPTEMBER 2, 2025
    Update
  2. PRESS RELEASE DATED AUGUST 18, 2025
    Update
  3. PRESS RELEASE, DATED MAY 21, 2024.
    News
  4. marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
    News
  5. Announces Cash Tender Offer for up to 7,750,000
    News
  6. PharmaCyte Biotech to Implement Second $10-Million
    News
  7. PharmaCyte Biotech Board of Directors Announces
    Update
  8. PharmaCyte Biotech Reaches Cooperation Agreement
    Update
  9. PharmaCyte Biotech Rebukes Iroquois’ Commencement
    News
  10. PharmaCyte Biotech Commences First Phase of Two-Phase
    News
  11. Reports Positive Interim Results in Malignant Ascites Mouse Model Study
    News
  12. LAS VEGAS, NV, July 11, 2022 (BUSINESS WIRE) -- PharmaCyte Biotech,
    Results
  13. PharmaCyte Biotech Issues Follow-Up Response
    News
  14. Appoints Dr. Matthias Löhr to Board of Directors
    Update
  15. 8-K exhibit EX-99.1
    Update

See a number that looks wrong?